IMMUNOMET

ImmunoMet Therapeutics, founded in 2015 as a spin-off from the Korean company HanAll Biopharma, owns a large library of biguanides with the potential for development, internally or with partners, as novel treatments for cancer and/or diseases of fibrosis. The company, headquartered in JLABS @ TMC in Houston has raised $39 MM since its inception.

Also known as: Immunomet Therapeutics Inc.

Primary location: Houston United States